Gilead Sciences, Inc.

(NASDAQ Global Select)
Back to all articles
Bullish +65

Why is Arcellx stock up 80% today? Gilead's $7.8B answer

AI-generated analysis

πŸ“ˆ Gilead Sciences agreed to acquire Arcellx for $7.8 billion in an all-cash deal, valuing the company at $115 per share plus a potential $5 contingent value right.

πŸ’° The acquisition includes a CVR that pays out if anito-cel achieves $6 billion in cumulative global net sales by the end of 2029.

πŸ₯ Gilead is acquiring anitocabtagene autoleucel (anito-cel), a BCMA-directed CAR-T therapy for relapsed or refractory multiple myeloma.

⏳ The FDA is expected to make a decision on anito-cel by December 23, 2026, keeping the asset in a near-launch window.

πŸ“Š Gilead expects the acquisition to be accretive to earnings per share starting in 2028, assuming regulatory approval is obtained.

🀝 The deal consolidates control of a program Gilead has been collaborating on with Arcellx since 2022.

πŸ“‰ Gilead's stock dipped about 1% in premarket trade following the announcement of the large cash commitment.

πŸ”¬ Anito-cel faces competition from established players like Johnson & Johnson and Legend Biotech's Carvykti in the multiple myeloma CAR-T market.

πŸ“ˆ Arcellx stock surged roughly 80% in premarket trading as it repriced toward the definitive buyout price of $115 per share.

🏒 Gilead already owns approximately 11.5% of Arcellx's outstanding shares before the transaction closes.

Bullish Signals
  • Gilead Sciences agreed to acquire Arcellx for $7.8 billion in an all-cash deal, significantly expanding its presence in the high-growth cell therapy market.
  • The acquisition of anitocabtagene autoleucel (anito-cel) targets a large commercial opportunity in the multiple myeloma CAR-T category with a potential $6 billion sales milestone.
  • Gilead expects the deal to be accretive to earnings per share starting in 2028, assuming FDA approval is granted for the lead therapy.
  • The transaction consolidates control of a program Gilead has collaborated on since 2022, leveraging existing knowledge and reducing integration risk.
  • The FDA decision on anito-cel is expected by December 23, 2026, providing a clear near-term timeline for potential revenue generation.
Risk Factors
  • Gilead's stock dipped about 1% in premarket trade following the announcement of the $7.8 billion cash commitment to acquire Arcellx.
  • The acquired asset faces intense competition from established players like Johnson & Johnson and Legend Biotech in the multiple myeloma CAR-T category.
Full Analysis
Gilead Sciences has agreed to acquire Arcellx in an all-cash deal valued at approximately $7.8 billion, marking a significant strategic expansion into the cell therapy space. The transaction is structured as a tender offer followed by a merger, with Gilead already holding an 11.5% stake in Arcellx prior to the closing of the deal. Gilead will pay $115 per share in cash at closing, plus a contingent value right (CVR) worth up to $5 per share if specific sales milestones are met. The CVR is tied to anito-cel reaching cumulative global net sales of at least $6 billion by the end of 2029, representing a total premium of roughly 87% over Arcellx's previous closing price. The acquisition targets anitocabtagene autoleucel (anito-cel), an investigational BCMA-directed CAR-T therapy for relapsed or refractory multiple myeloma. Gilead expects the deal to be accretive to earnings per share starting in 2028, assuming FDA approval is granted by the anticipated decision date of December 23, 2026. This move consolidates control over a program Gilead has collaborated on since 2022, positioning it against established competitors like Johnson & Johnson and Legend Biotech. The acquisition aims to capture a large commercial opportunity in the multiple myeloma CAR-T category while leveraging Gilead's existing manufacturing and distribution capabilities.